Literature DB >> 18197613

Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.

Shinya Oishi1, Saori Ito, Hiroki Nishikawa, Kentaro Watanabe, Michinori Tanaka, Hiroaki Ohno, Kazuki Izumi, Yasuko Sakagami, Eiichi Kodama, Masao Matsuoka, Nobutaka Fujii.   

Abstract

Reported herein are the design, biological activities, and biophysical properties of a novel HIV-1 membrane fusion inhibitor. alpha-Helix-inducible X-EE-XX-KK motifs were applied to design an enfuvirtide analogue 2 that exhibited highly potent anti-HIV activity against wild-type HIV-1, enfuvirtide-resistant HIV-1 strains, and an HIV-2 strain in vitro. Indispensable residues for bioactivity of enfuvirtide, including the residues interacting with the N-terminal heptad repeat and the C-terminal hydrophobic residues, were identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197613     DOI: 10.1021/jm701109d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

Authors:  Lifeng Cai; Chungen Pan; Liang Xu; Yuan Shui; Keliang Liu; Shibo Jiang
Journal:  FASEB J       Date:  2011-11-15       Impact factor: 5.191

Review 2.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

3.  Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Authors:  Dirk Eggink; Ilja Bontjer; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

5.  A suite of modular fluorescence assays interrogate the human immunodeficiency virus glycoprotein-41 coiled coil and assist in determining binding mechanism of low molecular weight fusion inhibitors.

Authors:  Miriam Gochin
Journal:  Assay Drug Dev Technol       Date:  2012-08-16       Impact factor: 1.738

6.  Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

Authors:  Shidong Chu; Hardeep Kaur; Ariana Nemati; Joseph D Walsh; Vivian Partida; Shao-Qing Zhang; Miriam Gochin
Journal:  ACS Chem Biol       Date:  2015-02-17       Impact factor: 5.100

7.  HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

Authors:  Kazuki Shimane; Kumi Kawaji; Fusako Miyamoto; Shinya Oishi; Kentaro Watanabe; Yasuko Sakagami; Nobutaka Fujii; Kazuya Shimura; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

Review 8.  Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.

Authors:  M L Bellows; C A Floudas
Journal:  Curr Drug Targets       Date:  2010-03       Impact factor: 3.465

9.  Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.

Authors:  Kazuki Izumi; Eiichi Kodama; Kazuya Shimura; Yasuko Sakagami; Kentaro Watanabe; Saori Ito; Tsuyoshi Watabe; Yukihiro Terakawa; Hiroki Nishikawa; Stefan G Sarafianos; Kazuo Kitaura; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

10.  Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

Authors:  Kazuki Izumi; Kumi Kawaji; Fusasko Miyamoto; Kazuki Shimane; Kazuya Shimura; Yasuko Sakagami; Toshio Hattori; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Int J Biochem Cell Biol       Date:  2013-01-26       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.